Ganciclovir Antagonizes the Anti-human Immunodeficiency Virus Type 1 Activity of Zidovudine and Didanosine in Vitro

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 May 1

PMID 1510405

Citations 7

Authors

D J Medina

G D Hsiung

J W Mellors

Affiliations

Soon will be listed here.

Abstract

In studies examining potential interactions between ganciclovir (GCV) and either zidovudine (AZT) or didanosine (DDI) in H9 cells, GCV was found to consistently reduce the anti-human immunodeficiency virus type 1 potency of both AZT and DDI. In the presence of GCV, the 50% effective doses of AZT and DDI were increased three- to sixfold, depending on the molar ratio of drugs and the measure of human immunodeficiency virus type 1 replication (p24 antigen, reverse transcriptase activity, or infectious virus yield). Multiple dose-effect analysis revealed strong antagonism between GCV and either AZT or DDI (combination indices, 2.2 to 6.7). This antagonistic effect occurred at drug concentrations that were well below the cytotoxic range. At higher drug concentrations, the combination of GCV and AZT was synergistically cytotoxic (combination indices, less than 1.0), whereas GCV and DDI were only additively cytotoxic (combination indices, ca. 1.0). Thus, the combination of GCV with AZT or DDI may result in antiviral antagonism and either synergistic (AZT-GCV) or additive (DDI-GCV) cytotoxicity.

Citing Articles

A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo.

Vanpouille C, Bernatchez J, Lisco A, Arakelyan A, Saba E, Gotte M AIDS. 2017; 31(11):1519-1528.

PMID: 28657962 PMC: 5541768. DOI: 10.1097/QAD.0000000000001532.

Mysteries and miracles: personal recollections in clinical and diagnostic virology.

Hsiung G Clin Diagn Virol. 1995; 3(Suppl 1):1-81.

PMID: 15566822 PMC: 7135423. DOI: 10.1016/0928-0197(95)80003-4.

The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Kewn S, Hoggard P, Sales S, Johnson M, Back D Br J Clin Pharmacol. 2001; 50(6):597-604.

PMID: 11136299 PMC: 2015020. DOI: 10.1046/j.1365-2125.2000.00302.x.

Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Stretcher B Clin Pharmacokinet. 1995; 29(1):46-65.

PMID: 7586898 DOI: 10.2165/00003088-199529010-00006.

Antiviral therapy for human immunodeficiency virus infections.

De Clercq E Clin Microbiol Rev. 1995; 8(2):200-39.

PMID: 7542558 PMC: 172856. DOI: 10.1128/CMR.8.2.200.

References

Chambers R, Terada M, Kufe D, Ohno T . Shaking HIV-1 infected cells indicates novel behavior of MN strain. AIDS Res Hum Retroviruses. 1991; 7(5):459-63. DOI: 10.1089/aid.1991.7.459. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Dolin R, Lambert J, Morse G, Reichman R, Plank C, Reid J . 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis. 1990; 12 Suppl 5:S540-9; discussion S549-51. View

Cheng Y, Dutschman G, Bastow K, Sarngadharan M, Ting R . Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem. 1987; 262(5):2187-9. View

Gupta P, Balachandran R, Ho M, Enrico A, Rinaldo C . Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol. 1989; 63(5):2361-5. PMC: 250658. DOI: 10.1128/JVI.63.5.2361-2365.1989. View

Shepp D, Dandliker P, de Miranda P, Burnette T, Cederberg D, Kirk L . Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985; 103(3):368-73. DOI: 10.7326/0003-4819-103-3-368. View

Haertle T, Carrera C, Wasson D, Sowers L, Richman D, Carson D . Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem. 1988; 263(12):5870-5. View

Richman D, Fischl M, GRIECO M, Gottlieb M, Volberding P, Laskin O . The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):192-7. DOI: 10.1056/NEJM198707233170402. View

Reichert C, OLeary T, Levens D, Simrell C, Macher A . Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol. 1983; 112(3):357-82. PMC: 1916399. View

10.

Johnson V, Merrill D, Videler J, Chou T, Byington R, Eron J . Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991; 164(4):646-55. DOI: 10.1093/infdis/164.4.646. View

11.

Causey D . Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment. J Acquir Immune Defic Syndr (1988). 1991; 4 Suppl 1:S16-21. View

12.

Yang Z, Crouch J, Feng J, Chou T, Hsiung G . Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. Antiviral Res. 1990; 14(4-5):249-65. DOI: 10.1016/0166-3542(90)90006-s. View

13.

Lambert J, Seidlin M, Reichman R, Plank C, Laverty M, Morse G . 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990; 322(19):1333-40. DOI: 10.1056/NEJM199005103221901. View

14.

Hochster H, Dieterich D, Bozzette S, Reichman R, Connor J, Liebes L . Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990; 113(2):111-7. DOI: 10.7326/0003-4819-113-2-111. View

15.

Vogt M, Hartshorn K, Furman P, Chou T, Fyfe J, Coleman L . Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987; 235(4794):1376-9. DOI: 10.1126/science.2435003. View

16.

Buhles Jr W, Mastre B, TINKER A, Strand V, Koretz S . Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis. 1988; 10 Suppl 3:S495-506. DOI: 10.1093/clinids/10.supplement_3.s495. View

17.

Armstrong D, Gold J, Dryjanski J, Whimbey E, Polsky B, Hawkins C . Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103(5):738-43. DOI: 10.7326/0003-4819-103-5-738. View

18.

Vujcic L, Shepp D, Klutch M, Wells M, Hendry R, Wittek A . Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis. 1988; 157(5):1047-50. DOI: 10.1093/infdis/157.5.1047. View

19.

Jacobson M, de Miranda P, Gordon S, Blum M, Volberding P, Mills J . Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy. J Infect Dis. 1988; 158(2):489-90. DOI: 10.1093/infdis/158.2.489. View

20.

Schinazi R, Chou T, Scott R, Yao X, Nahmias A . Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother. 1986; 30(3):491-8. PMC: 180586. DOI: 10.1128/AAC.30.3.491. View